Pharmaceutical stocks have become the brightest, and institutions believe that the future market with high performance and bid increase is worth looking forward to.
The index remained high for three days and fell sharply in the afternoon. Photovoltaic, lithium and other new energy sources strengthened, while silver, gold, nonferrous zinc, oil service and other sectors fell against the market pharmaceutical stocks became the most beautiful ones on the market today, and most of the concept sectors with the highest increase were pharmaceutical subdivision concepts. Covid-19 detection sector pulled up in the afternoon, Shanghai Labway Clinical Laboratory Co.Ltd(301060) , Guangzhou Wondfo Biotech Co.Ltd(300482) , Fujian Cosunter Pharmaceutical Co.Ltd(300436) , Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) and other stocks rose by more than 10%.
pharmaceutical sector broke out across the board
411 of the 431 shares in the pharmaceutical and biological sector rose today, and China Meheco Group Co.Ltd(600056) rose by a single word limit at the opening of trading today, with a cumulative increase of nearly 80% in the past 10 trading days news, yesterday, China Meheco Group Co.Ltd(600056) announced that in March 9th, Pfizer Inc signed a supply agreement, will be responsible for Pfizer’s COVID-19 virus treatment drug Nai matwey / Ritonavir Tablets packaging in 2022, the commercial operation of the Chinese mainland market. However, the company said today that it expects the scale of relevant businesses to account for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
in addition, stimulated by the news that covid-19 oral medicine in yanyeyi, Japan is about to be put into clinical treatment, Pku Healthcare Corp.Ltd(000788) , Changjiangrunfa Health Industry Co.Ltd(002435) and Changjiangrunfa Health Industry Co.Ltd(002435) all rose by one word today
Wuxi Apptec Co.Ltd(603259) rose by more than 9% today. Yesterday, Wuxi Apptec Co.Ltd(603259) released its main business data from January to February this year. Its on-hand orders and sales revenue grew by more than 65% year-on-year, a record high. Wuxi Apptec Co.Ltd(603259) is expected to grow by 65% – 68% year-on-year in the first quarter of 2022. Looking forward to the whole year, the company’s revenue is expected to increase by 65% – 70% year-on-year.
high performance bid increase
funds are optimistic about these
At present, covid-19 epidemic continues to affect human production and life. With the emergence of new confirmed cases in many places across the country, epidemic prevention is still a part of normalization in life. This year’s government work report proposes to strengthen the research and prevention of virus mutation, accelerate the research and development of vaccines and specific drugs, continue to do a good job in vaccination, scientifically and accurately deal with local epidemics, and maintain normal production and living order in the field of medicine, centralized procurement of drugs and high-quality consumables, vaccine supervision and medical insurance payment reform have been included in the expected development goals of 2022
In fact, the pharmaceutical sector experienced a significant retreat in 2021. For the follow-up trend of the pharmaceutical sector, institutions generally believe that after the early adjustment, the negative factors of the sector have been fully released, the investment value is prominent, and the valuation is at the bottom of history. Under the current policy background, companies with fast industrial development and fast growth will become the outlet of the market, At present, it is in the performance disclosure period of annual report and first quarter report. Companies with high growth or exceeding expectations may be favored by the market.
Securities Times · databao combed that from the market performance after the Spring Festival, more than 400 shares rose by an average of 3.88%, outperforming the market 39 shares rose by more than 20%, two new shares of Hefu China and Chengda pharmaceutical doubled, and Nanjing Hicin Pharmaceutical Co.Ltd(300584) , Changjiangrunfa Health Industry Co.Ltd(002435) , China Meheco Group Co.Ltd(600056) and other shares rose by more than 70%
At present, 306 pharmaceutical and biological concept stocks have issued the performance forecast or express report for 2021. From the lower limit of the forecast and the express report data, 249 listed companies have achieved profits in 2021, and the net profit attributable to the parent company in 2021 of Chongqing Zhifei Biological Products Co.Ltd(300122) , Kangmei Pharmaceutical Co.Ltd(600518) , Wuxi Apptec Co.Ltd(603259) , Zhejiang Orient Gene Biotech Co.Ltd(688298) , Zhejiang Nhu Company Ltd(002001) , all exceeded 4 billion yuan 184 shares were included in the list of excellent performance (profitable and increased year-on-year), of which 64 shares doubled year-on-year Chimin Health Management Co.Ltd(603222) led the increase. The company’s operating revenue in 2021 was 1.107 billion yuan, a year-on-year increase of 26.14%; The net profit attributable to the parent company was 147 million yuan, with a year-on-year increase of 220539%. The business profit of the company’s medical device sector increased significantly.
Since the Spring Festival, the net purchase amount of northbound capital of 30 shares has recorded a positive value. The net purchase amount of northbound capital of Wuxi Apptec Co.Ltd(603259) , Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) has been increased by 932 million yuan and 519 million yuan respectively. The net purchase amount of northbound capital of Dong-E-E-Jiao Co.Ltd(000423) , Shenzhen Kangtai Biological Products Co.Ltd(300601) , Dian Diagnostics Group Co.Ltd(300244) , Zhejiang Medicine Co.Ltd(600216) has exceeded 100 million yuan.
Today, the primary net inflow of the main force of the bio medicine sector, which is now dominated by the bio medicine sector, is as high as 4.4664 billion yuan, with 104 medical concept stocks having net infloinfloin. The net inflow of 104 medical concept stocks has been a net inflow, with 603 Wuxi Apptec Co.Ltd(603259) \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\thenet inflow of more than 10 shares such as exceeded 100 million yuan.
